B.S./M.S./ PhD in Engineering, Bioengineering, Biotechnical Engineering, Industrial or Manufacturing Engineering, or MS/PhD in Materials Science or Physical…From Illumina, Inc. – Mon, 24 Oct 2016 20:32:26 GMT – View all San Diego jobs
We are currently looking for a HR Generalist to work for a leading San Diego biotechnology company. Specializes in recruiting top talented professionals for San…From Indeed – Mon, 24 Oct 2016 19:28:44 GMT – View all San Diego jobs
SAN DIEGO, Oct. 24, 2016 /PRNewswire/ — Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance according to research presented by Polaris at the 2016 American Association for Cancer Research Tumor Immunology and Immunotherapy conference in Boston. These findings suggest that ADI-PEG 20 could potentially enhance the activity of anti-tumor immune therapies, including checkpoint inhibitors.
To investigate the potential effect of ADI-PEG 20 on immune cells, healthy human peripheral blood mononuclear cells were treated with ADI-PEG 20 under resting and activation conditions and were characterized by immune cell phenotyping using flow cytometry. Researchers found that under stimulation conditions ADI-PEG 20 treatment markedly boosted T cell activation (as measured by CD69 expression) while moderating T cell exhaustion (CTLA-4 and PD-1 levels remained low, similar to that at a resting state). Moreover, ADI-PEG 20 reduced accumulation of regulatory T cells, which are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells. As such, it was hypothesized that ADI-PEG 20 may improve immunogenicity of non-immunogenic tumors.
The poorly immunogenic mouse melanoma B16-F10 model was used to test the hypothesis. Analysis of the tumor sections revealed that five out of six ADI-PEG 20 treated animals had a large number of T cells in their tumors; only one ADI-PEG 20 treated mouse had very little tumor T cell infiltrate, similar to the non-treated controls, demonstrating that ADI-PEG 20 can improve tumor immunogenicity. ADI-PEG 20 also inhibited growth of the B16-F10 tumor in vitro and in vivo.
“We are excited about the discovery of ADI-PEG 20’s ability to regulate cellular immune response, thereby expanding its mechanism of action for its anti-tumor activity. We are conducting further research to assess which combinations of ADI-PEG 20 with PD1/PD-L1 blockers will further enhance these drugs’ anti-tumor efficacy,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris Pharmaceuticals, Inc.
About ADI-PEG 20
ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine dependency.
About Polaris Group
Polaris Group is a multinational biotechnology company specializing in the research and development of novel pharmaceuticals to treat cancer. The company’s lead therapeutic, ADI-PEG 20, is a novel biologic in late stage clinical development. It has been tested in more than twenty clinical trials globally for a wide variety of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. As a fully integrated company, Polaris is engaged in applying protein structure-based drug design technology to develop novel drug candidates for cancers, conducting clinical studies at top-tier cancer centers worldwide, and manufacturing all clinical materials at its certified cGMP facilities in northern California.
For additional information please visit www.polarispharma.com.
SOURCE Polaris Group
Positions: Sr.Chemist and Production Chemist
Industry: Pharmacuetical Company
Location: Mira Mesa
Chemist will perform analytical testing utilizing LCMS, HPLC, GC and other lab instruments. Must have experience in one or more of […
Article One Partners (AOP), the world’s largest online patent and technical literature research community is seeking immediate, part-time Technical Literature Researchers to support our growing inventory of technical and research studies […
SAN FRANCISCO, Oct. 24, 2016 /PRNewswire/ — Benchling, the next-generation life science R&D software company, announced that is has raised $7 million in new funding. This latest funding round was led by Thrive Capital and included participation from Andreessen Horowitz, Y Combinator partner Geoff Ralston, Sequoia partner Matt Huang, CXO of Tencent David Wallerstein, and actor/tech investor Ashton Kutcher. The company has now raised over $13 million from investors who have collectively funded SpaceX, Tesla, Facebook, and Airbnb, among other seminal technology companies.
Since its founding in 2012, Benchling has become a leading innovator in the R&D technology space. The company provides an integrated cloud-based software platform consisting of lab notebook, LIMS, and molecular biology tools to over 40,000 academic and industry scientists. These users represent more than 10,000 academic institutions and over 150 companies.
“Drug discovery is becoming more complex and costly, while offering significantly lower returns. In turn, scientists are generating more data and working on more complicated problems than ever, but the ways they manage that data and collaborate have barely changed in the past decade. The industry mostly runs on paper, spreadsheets, and otherwise clunky and outdated software that’s designed with little scientist input,” said Sajith Wickramasekara, Founder & CEO of Benchling. “Benchling develops its software with real scientist workflows in mind, so that scientists’ tools can streamline their research rather than impede it. Instead of spending upwards of 30% of their time taking notes and searching through disjointed records systems, scientists can focus on science.”
Biotechnology companies of all types, from emerging players through established pharmaceutical organizations, have adopted Benchling, viewing its platform as a competitive advantage over existing legacy systems. Customers have reported unprecedented scientist adoption, and on average, Benchling’s industry scientist users report a satisfaction rating of over 90% when comparing the platform to their previous tools.
“Benchling represents a refreshing, intuitive, and modern platform that maps to the life scientist’s brain. We love its focus on the user experience including its convenient chat-driven support, its ability to rapidly integrate with diverse internal and external services, and the profound engineering foundations it’s built on,” said Hari Jayaram, Associate Director, Protein Engineering and Computational Biology at Editas. “All of these ensure high daily use and a significant value-add to our research.”
“Advances in the possibilities of life sciences research and dramatic reduction in costs is leading to a rapidly expanding set of innovations and new companies. The software for collaboration and data management though has not kept pace,” said Miles Grimshaw, Investor at Thrive Capital. “Building on our partnerships with the market leading collaboration software in other verticals, such as Greenhouse for recruiters and Github for engineers, we are excited to support Benchling in building the best collaboration software for researchers.”
The company plans to use the new funding to expand scientific operations, broaden development across more therapeutic areas, and further expand its platform to be increasingly comprehensive. In the coming quarter Benchling plans to release a product that bridges structured and unstructured scientific data.
Benchling is accelerating life science R&D by providing an intelligent, cloud-based software platform that streamlines research processes from start to finish. The technology accomplishes this through natively integrated lab notebook, LIMS, and molecular biology tools that consolidate data in one place and facilitate team and external collaboration. Headquartered in San Francisco, CA, Benchling is used by scientists in industry and academia around the globe. For more information about Benchling, please visit http://www.benchling.com.
Tata Trusts & University of California San Diego partner to establish Tata Institute for Active Genetics and Society (TIAGS)
Institute represents ground-breaking binational scientific partnership to undertake research that will advance science & technology to support human needs
SAN DIEGO, Oct. 24, 2016 /PRNewswire-USNewswire/ — The University of California San Diego today announced its collaboration with the India-based philanthropic organization Tata Trusts, which includes the Sir Dorabji Tata Trust, the Sir Ratan Tata Trust and the Tata Education and Development Trust, to establish the Tata Institute for Active Genetics and Society (TIAGS), a partnership between the university and research operations in India. A complementary unit will support a collaborative research enterprise in India (TIAGS-India). The goal of the Institute is to push the boundaries of bioscience in support of human needs and society, and to build scientific capacity in India. The Institute will specifically advance global science and technology research to ultimately find solutions to address some of the world’s most pressing issues, ranging from health care to agriculture.
“As one of the of the world’s top research institutions, we are committed to the global good,” said UC San Diego Chancellor Pradeep K. Khosla. “This international collaboration to establish the Tata Institute for Active Genetics and Society will spark new scientific research and discoveries that will ultimately help us tackle some of the biggest challenges that face humankind in a socially conscious and ethical manner.”
UC San Diego, which is ranked among the top 15 universities in the world, will match the gift to create 10 endowed chairs, designed to attract and retain top scientists and faculty focused on research that aligns with the Institute’s goals.
“UC San Diego’s mission to advance society and drive economic impact aligns with our goals, as a country, to build a skilled scientific workforce and to grow the impact and scope of our research enterprise,” said Ratan Tata, Chairman, Tata Trusts. “Together, we will promote bioscience research, discoveries and education that will benefit populations around the globe.”
The initiative’s inaugural basic research enterprise—a thrust in Active Genetics—will be focused on applications of “active genetics” to improve human health and agriculture. Developed at UC San Diego, active genetics is a new field of genetics that incorporates a novel method, called “gene drive,” for generating mutations in both copies of a gene in a single generation. Research efforts spearheaded by the Tata Institute for Active Genetics and Society will require and foster partnerships with scientific colleagues and government agencies in both India and the United States.
“Recent discoveries in genetics have created a new understanding of genes—not only just what they are or how they work, but also how they change or can be altered,” said Ethan Bier, Professor of Biology at UC San Diego and Paul Allen Foundation Distinguished Investigator, who has pioneered the field of active genetics with UC San Diego postdoctoral fellow, Valentino Gantz. “This understanding, combined with novel technology of gene editing, has opened new areas for exploration that have potential applications in areas ranging from new health therapies, to prevention of the spread of disease, to agriculture uses.”
One of the objectives of the Institute’s research efforts will be to develop strains of mosquitoes that are unable to propagate malarial parasites, Bier said. This effort, currently underway in collaboration with Anthony James, Distinguished Professor of Microbiology and Molecular Genetics at the University of California Irvine, could lead to the development of an effective way to combat vector-borne diseases, including malaria, a debilitating disease that afflicts hundreds of millions of people in tropical regions around the world. The researchers at UC San Diego and its partner institute in India also plan to apply active genetic technology to improve crops, enable new forms of cell therapy and develop ways to control microbial pathogens.
In addition to a thrust in Active Genetics, the Institute will also include a parallel thrust in Society and Ethics, which will leverage UC San Diego’s expertise in health, policy and economics, and ethics, and link Indian experts with larger research and education initiatives to effect societal progress. An important goal of this thrust will be to provide ethical guidance for the research activities in bioscience and the application of new technologies developed from the research in efforts to improve human health, agriculture and the environment. That will involve bringing researchers in India together with scholars from UC San Diego in the humanities and social sciences, such as Anita Raj, who directs the UC San Diego Center on Gender Equity and Health; Karthik Muralidharan, a development economist whose research areas include education, health, social protection, program evaluation and service delivery; and Craig Callender, whose work focuses on environmental ethics.
Leveraging cross-national, joint training opportunities to prepare future generations of scientific leaders in biotechnology and life sciences, the innovative binational structure of the Tata Institute for Active Genetics and Society will streamline the building of scientific capacity and transfer of knowledge and technology to India. It will also serve to advance the biotechnology sector in India and establish a model for other global scientific endeavors.
Suresh Subramani, Distinguished Professor of Biological Sciences at UC San Diego, will be the inaugural director. “It is an honor to lead an institute of such significance to both UC San Diego and to India,” he said.
The Institute will also host annual opportunities to meet and discuss ground-breaking genetics technologies, as well as to address safety, efficiency and ethics conversations around emerging fields of genetics. Annual symposia are planned in India to consider discoveries, opportunities and challenges for the future.
The collaboration with the Tata Trusts is an honor for UC San Diego. “Growing up in India, I looked up to the Tata Family as champions of philanthropy for the human good,” Khosla said. “The Tata family’s impact to bring about societal change and to build the country’s infrastructure has been immeasurable. When Mr. Tata visited with researchers at UC San Diego, he was immediately drawn to the impact of the science and its strong linkages to bettering human society. It’s a powerful partnership with unlimited potential to improve the world.”
About Tata Trusts:
Tata Trusts is amongst India’s oldest, non-sectarian philanthropic organizations that work in several areas of community development. Since its inception, Tata Trusts has played a pioneering role in transforming traditional ideas of philanthropy to make impactful sustainable change in the lives of the communities served. Through direct implementation, co-partnership strategies and grant making, the Trusts support and drive innovation in the areas of education; healthcare and nutrition; rural livelihoods; natural resources management; enhancing civil society and governance and media, arts, crafts and culture. Tata Trusts continues to be guided by the principles of its Founder, Jamsetji Tata, and through his vision of proactive philanthropy, the Trusts catalyze societal development while ensuring that initiatives and interventions have a contemporary relevance to the nation. For more information, please visit: http://www.tatatrusts.org/
Facebook: Tata Trusts
Giving to UC San Diego
At the University of California San Diego, we constantly push boundaries and challenge expectations. Established in 1960, UC San Diego has been shaped by exceptional scholars who aren’t afraid to take risks and redefine conventional wisdom. Today, as one of the top 15 research universities in the world, we are driving innovation and change to advance society, propel economic growth and make our world a better place. This positive impact extends far beyond the walls of our campus and is made possible with generous private support. Learn more at www.ucsd.edu.
SOURCE UC San Diego
SAN DIEGO, Oct. 24, 2016 /PRNewswire/ — Viriom Inc. is pleased to announce the appointment of Janet Hammond, MD, PhD as a member of its Scientific Advisory Board. Dr. Hammond most recently served as Senior VP and Global Head of Infectious Diseases at F. Hoffmann-La Roche managing early clinical development strategy and implementation.
Dr. Hammond brings to the board her extensive knowledge in the areas of virology and infectious diseases, sound clinical expertise as well as ample regulatory experience. Dr. Hammond began her career as a Clinical Program Head of Clinical Discovery in Virology at GlaxoSmithKline (GSK), where she oversaw founding and development of a new department and its medical strategy, IND submissions, and clinical development of small molecules and vaccines. Subsequently she led the Early Clinical research team at Bristol-Myers Squibb responsible for HIV Early Development and Virology Life Cycle management. Dr. Hammond also served as CMO – Medical Affairs at Valeant, where she was responsible for clinical and pharmacovigilance activities around the globe.
“Dr. Hammond’s knowledge and experience in the fields of virology and infectious diseases will serve as an invaluable addition to Viriom’s efforts in developing innovative HIV treatments and will enrich its Scientific Advisory Board with a unique perspective,” said Nikolay Savchuk, PhD, Chairman of Viriom’s Scientific Advisory Board. “We believe that Dr. Hammond’s clinical expertise as well as experience in drug development and regulatory affairs will help support Viriom’s quest to provide more effective solutions for HIV patients.”
“Viriom’s innovative research aims at bringing to live the next generation of antiviral treatments that will not only be effective but also affordable, and I am delighted to become a part of the company’s renown team and contribute to advancing its novel therapies,” said Janet Hammond. After receiving her MD and PhD from the University of Cape Town, South Africa, Dr. Hammond has been an exceptionally active contributor to infectious disease therapies, leading the submission of three New Drug Applications (NDA) and Marketing Authorization Applications, more than ten supplemental NDAs, and more than ten Investigational New Drug (IND) applications in the past thirteen years.
Viriom’s Scientific Advisory Board members are prominent medical practitioners and scientists with extensive experience in virology and infectious diseases, working together to provide scientific and clinical advice on the development of novel and affordable therapies against life threatening infections including HIV and hepatitis B.
Viriom Inc. is a late-stage biotech company developing, manufacturing and distributing novel and affordable therapies against life threatening infections such as HIV and HBV. Viriom holds exclusive worldwide rights from F. Hoffmann-La Roche for VM1500, which it is presently developing as an oral AIDS treatment (Elpida® elpivirine) for active HIV infections; and as innovative longer-acting formulations of elpivirine for PrEP and PEP in high-risk patient populations. Viriom is also developing a proprietary therapeutic for chronic HBV infections. Viriom believes its drug candidates are capable of achieving breakthroughs in treatment and prevention of HIV and chronic HBV infections in both developing and developed countries. For more information, please visit www.viriom.com.
Frost & Sullivan Applauds GENEWIZ’s Commitment to Providing Cutting-edge Services in the Life Science Research Services Market
GENEWIZ’s implementation of diversified growth strategies has led to a stellar year and strong future positioning in the market
MOUNTAIN VIEW, Calif., Oct. 24, 2016 /PRNewswire/ — Based on its recent analysis of the life science research services market, Frost & Sullivan recognizes GENEWIZ with the 2016 North America Frost & Sullivan Company of the Year Award. GENEWIZ’s strategic decisions to reinvest in itself and expand its infrastructure, geographies, and customer channels have enabled it to emerge as a leader in this intensely competitive market. Its recent acquisition of Beckman Coulter Genomics (BCG) and implementation of multiple new genomics platforms demonstrate its commitment to growth and delivering cutting-edge research services using various genomics technologies and techniques.
GENEWIZ launched in 1999 as a service provider of Sanger sequencing services and is the undisputed market leader to this day. It has further diversified its services to include next-generation sequencing, gene synthesis, molecular biology, plasmid DNA preparation, and GLP-compliant research and development. It serves laboratories across academic, government, pharmaceutical, biotechnology, agriculture, environmental, clean energy, and clinical settings and has a large network of genomics laboratories in the United States, as well as facilities in Europe and Asia.
GENEWIZ’s ability to earn trust and respect while delivering excellent customer service has enabled them to expand successfully. The company also features stellar IT capabilities that provide a best-in-class customer interface, allowing GENEWIZ to integrate and communicate more effectively with customers. GENEWIZ’s customers keep coming back; positive word-of-mouth and brand awareness has propelled the company to become a leader across the genomics industry.
“When companies rise to the top of highly competitive and fragmented services markets, as GENEWIZ has, it is a clear indication of customer satisfaction and retention,” stated Frost & Sullivan Senior Industry Analyst Christi Bird. “Most of the world’s pharma/biotech companies now outsource work to GENEWIZ, a testament to the company’s excellent reputation in the industry and ability to serve as a trusted partner to the most elite research institutions globally.”
To expand its service offerings and infrastructure, GENEWIZ recently purchased several new cutting-edge genomics platforms including Illumina’s HiSeq X Ten sequencing platform, the highest throughput sequencing system available. GENEWIZ also announced the purchase of a PacBio Sequel sequencer for long-read sequencing applications, and a 10x Genomics Chromium to aid in de novo genome assembly and single-cell sequencing. In addition to building out its infrastructure, GENEWIZ is adding new service offerings, such as its recently launched proprietary immuno-sequencing and metagenomics testing services, and has several new capabilities in its development pipeline.
“GENEWIZ has exhibited best-in-class strategy implementation resulting in robust growth and industry success,” noted Bird. “By diversifying its growth strategy through M&A, increasing its throughput capacity, and adopting new technologies to expand its service offerings, GENEWIZ broadened its capacity for major growth gains.”
Overall, GENEWIZ’s range of services, cutting-edge technologies and techniques, fast turnaround times, excellent customer service, proprietary protocols, and value-additions have attracted significant business and cemented its leadership in the market.
“This Award is indeed an excellent recognition to GENEWIZ’s commitment to be the best in genomics services. Our dedicated employees reinforce this mentality and practice on a daily basis to ensure customers receive the best-in-class service within the industry, a true reflection of ‘solid science. superior service.,'” said Dr. Steve Sun, chief executive officer of GENEWIZ. “GENEWIZ is proud to be an instrumental contributor of the R&D ecosystem by being the leading genomics services provider, which enable research scientists uncover breakthroughs that transform the wellbeing of millions around the world.”
Each year, Frost & Sullivan presents this award to a company that has demonstrated excellence in devising a strong growth strategy and robustly implementing it. The recipient has shown strength in terms of innovation in products and technologies, leadership in customer value, as well as speed in response to market needs. In short, the awards team looks at the emerging market participants in the industry and recognizes their best practices that are positioned for future growth excellence.
Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.
GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high-throughput sequencing, bioinformatics, and GLP regulatory-compliant services.
Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a global network of laboratories in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, WeChat and Weibo.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.
P: +44 (0) 207.343.8314
Vice President, GENEWIZ
SOURCE Frost & Sullivan
Create detailed implementation plans based on Core Informatics Customer Implementation Methodology. Experience within the biotech or pharmaceutical industry is…From Core Informatics – Mon, 24 Oct 2016 10:52:03 GMT – View all San Diego jobs